TScan Therapeutics, Inc. (TCRX) is a Healthcare stock trading at $0.78 (as of 2026-08-21), with a market capitalization of $101.28M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
TScan Therapeutics, Inc. is a preclinical biopharmaceutical company developing T cell receptor-engineered T cell therapies for hematologic malignancies and solid tumors, and vaccines targeting infectious diseases such as SARS-CoV-2. It also has a collaboration with Novartis to identify novel cancer antigens from patient T cells.
Understand TScan Therapeutics, Inc.: how it makes money
TScan Therapeutics develops T cell receptor-engineered T cell therapies for cancer and also works on infectious disease vaccines, and it makes money through collaboration and license agreements (for example, a collaboration and license agreement with Novartis).
The company’s near-term profit model relies on collaboration and license revenue rather than product sales, as indicated by zero reported revenue in the latest period.
Revenue by segment (latest quarter)
Collab & License
$0.0B
Business quality (Weak): Limited disclosed operating detail beyond development progress and a single reported revenue line, and the latest quarter shows zero revenue with very large operating losses, which makes near-term fundamentals highly dependent on future collaboration payments and clinical and manufacturing milestones.
Bull case
Broad pipeline across hematologic malignancies and solid tumors: It is developing multiple T cell receptor-engineered T cell programs, including TSC-100 and TSC-101 for hematologic malignancies and TSC-200 through TSC-204 for solid tumors.
Partnering model is explicit: The business includes a collaboration and license agreement with Novartis, and collaboration and license revenue is the company’s identified revenue line.
Translational targeting and process signals are tracked: It reports that 55% of solid tumor screened patients qualify for at least one T cell receptor therapy in ImmunoBank, and it reports a commercial-ready manufacturing process duration of 12 days.
Bear case
No reported revenue in the latest quarter: For the period ended 2026-03-31, revenue_b is 0.0B, so operating performance cannot yet be supported by product cash flows based on the provided data.
Very large operating loss: The operating_margin_pct is -2967.3, indicating substantial operating losses in the latest period.
Early-stage development and limited reported clinical detail: The company is preclinical-stage, and the provided trial-style metrics show patient counts such as 26 in the treatment arm and 12 in the control arm, which suggests results may be based on limited sample sizes.
Cost and resource changes: The company reports a workforce reduction percent of 30% (66 employees), which can be a sign of tight operating economics and potential execution risk if spending is constrained.